Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 16/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945145 | 0.83 | ALDH1A1 (0.41) | MAPT | |
| SCHEMBL21944847 | 0.82 | CETP (0.38) | CETPHCRTR1HCRTR2 | |
| SCHEMBL18005610 | 0.82 | CETP (0.38) | CETPHCRTR1HCRTR2MAPT | |
| SCHEMBL21945141 | 0.81 | ALDH1A1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL21945192 | 0.79 | MAPT (0.37) | CETPMAPT | |
| SCHEMBL21945238 | 0.79 | CYP11B1 (0.34) | MAPT | |
| SCHEMBL21945136 | 0.79 | KDM4E (0.40) | MAPT | |
| SCHEMBL21944845 | 0.78 | KDM4E (0.39) | MAPT | |
| SCHEMBL21945290 | 0.77 | HCRTR1 (0.32) | HCRTR1HCRTR2 | |
| SCHEMBL21945068 | 0.77 | MAPT (0.36) | CETPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | CETP 478/4885HCRTR1 360/4885HCRTR2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.